Liraglutide and Peripheral Artery Disease
NCT04881110 on ClinicalTrials.gov · last registry update 2025-03-03
Finished 31 December 2022, after enrolling 60 people. Primary outcome, as filed: Peripheral Transcutaneous Oxygen Pressure. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P4
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- University of Campania Luigi Vanvitelli
- Sponsor type
- Other
- Enrollment
- 60
- Started
- 2021-02-01
- Primary completion
- 2022-12-31 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Peripheral Transcutaneous Oxygen Pressure
Conditions studied
Type 2 Diabetes · Peripheral Arterial Disease
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.